

Product Data Sheet

Product Name: VVD 065
Cat. No.: GC81040

Chemical Properties

Cas. No. 3034876-85-9


Formula $C_{16}H_{16}ClN_5O_2$ M.Wt 345.78

Solubility Storage Store at 4°C, stored under nitrogen

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure



Background

VVD 065 is an orally active KEAP1 -dependent NRF2 molecular glue degrader with a KEAP1 K D of 65 nM. VVD 065 covalently engages KEAP1 at Cys151, allosterically stabilizes KEAP1 - CUL3 complex formation and enhances NRF2 polyubiquitination and proteasomal degradation. VVD 065 can be used for the research of esophageal squamous cell carcinoma, lung cancer, head-and-neck cancer, uterine cancers [1] [2] [3].

In Vivo, VVD-065 (0.3-50 mg/kg; p.o.; QD or BID) induces robust NRF2 degradation and tumor growth inhibition in KYSE70 xenograft mice^[3]. VVD-065 (2-50 mg/kg; p.o.; QD or BID) produces

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

potent, sustained tumor growth inhibition in HCC95 xenograft mice^[3]. VVD-065 (50 mg/kg; p.o.; QD or BID) drives tumor growth inhibition in diverse PDX models^[3]. VVD-065 (50 mg/kg; p.o.; QD) improves overall survival and reduces tumor burden in orthotopic KLN-205 syngeneic mice^[3].

In Vitro, VVD 065 potently reduces NRF2 protein levels in wild-type KEAP1/NRF2, KEAP1-mutant, and NRF2-mutant cellular settings, inhibits NRF2-dependent gene expression, and suppresses proliferation of NRF2-dependent cancer cell lines at low nM concentrations^[2].

References:

[1]. Adamopoulos C, et al. Turning KEAP1 against NRF2. Nat Chem Biol. 2026 May;22(5):680-682.

[2]. Roy N, et al. Abstract PR011: Discovery of VVD-065, a first-in class allosteric molecular glue of the Keap1-Cul3 E3-ligase complex for the treatment of NRF2 activated cancers. Mol Cncr Ther. 2023 Dec 01;22:PR011.

[3]. Roy N, et al. A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth. Cancer Discov. 2026 May 1;16(5):953-975.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA